Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Haematologica - 1 Jul 2016

Verstovsek Srdan, Vannucchi Alessandro M, Griesshammer Martin, Masszi Tamas, Durrant Simon, Passamonti Francesco, Harrison Claire N, Pane Fabrizio, Zachee Pierre, Kirito Keita, Besses Carlos, Hino Masayuki, Moiraghi Beatriz, Miller Carole B, Cazzola Mario, Rosti Vittorio, Blau Igor, Mesa Ruben, Jones Mark M, Zhen Huiling, Li Jingjin, Francillard Nathalie, Habr Dany, Kiladjian Jean-Jacques

Abstract excerpt

RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. This preplanned analysis occurred when all patients completed the Week 80 visit or discontinued. Objectives included evaluating the durability of the primary response (Week 32...

Topics

Join the communities discussing this publication.

Combined Modality Therapy
Hematocrit
Janus Kinases
Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Polycythemia Vera

Source

Open in PubMed Open full text

Identifiers

PMID: 27102499
DOI: 10.3324/haematol.2016.143644
PMCID: PMC5004461

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.PMID 27102499Read ↗

Polycythemia Vera: Rapid Evidence Review.Semantic proximity Read ↗

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.Semantic proximity Read ↗

The advantages and risks of ruxolitinib for the treatment of polycythemia vera.Semantic proximity Read ↗

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.Semantic proximity Read ↗

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.Semantic proximity Read ↗

Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.Semantic proximity Read ↗

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.Semantic proximity Read ↗

Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.Semantic proximity Read ↗

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.Semantic proximity Read ↗

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene.Semantic proximity Read ↗

Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.